Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: " The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer. | Radiation Oncology BioMed Central Research The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer Paul A Blood 1 and Tom Pickles2 Open Access Address 1Radiation Oncology BC Cancer Agency and University of British Columbia Victoria BC Canada and 2Radiation Oncology BC Cancer Agency and University of British Columbia Vancouver BC Canada Email Paul A Blood - pblood@ Tom Pickles - tpickles@ Corresponding author Published 18 May 2007 Received 20 March 2007 Radiation Oncology 2007 2 17 doi l748-7l 7X-2-17 Accepted 18 May 2007 This article is available from http content 2 l l7 2007 Blood and Pickles licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract_ Treatment guidelines recommend that curative radiation treatment of prostate cancer be offered only to men whose life expectancy is greater than 10 years. The average life expectancy of North American males is less than 10 years after age 75 yet many men older than 75 years receive curative radiation treatment for prostate cancer. This study used the provincial cancer registry in British Columbia Canada to determine median non-prostate cancer survival for men who were aged 75 to 82 years at start of radiation treatment. Median survival was found to be greater than 10 years in men aged up to 80 years at the start of their radiation treatment. This finding suggests that radiation oncologists are able to appropriately select elderly men with greater than average life expectancy to receive curative radiation treatment. Background It is generally
